Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$178.11M$178.11Mderived+31.9% vs Q4 2022 Net Income$36.17M$36.17Mderived+6.6% vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$96,140,000+35.1% Operating Incomederived$53,980,000+42.7% Operating Cash Flowderived$23,864,000+56.7% Free Cash Flowderived$14,422,000+61.8% Margins · derivedGross margin54.0%+1.3 pt vs Q4 2022
Operating margin30.3%+2.3 pt vs Q4 2022
Net margin20.3%−4.8 pt vs Q4 2022
ended Dec 31, 2023 · filed Feb 29, 2024 · 60 d after period end